Management Infertility by Hormones Replacement Therapy in Women with Polycystic Ovarian Syndrome

Authors

DOI:

https://doi.org/10.25156/ptj.v10n1y2020.pp170-174

Keywords:

Infertility, Polycystic ovary syndrome, Follicle-stimulating hormone, Luteinizing hormone, Progesterone

Abstract

Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder characterized by multiple hormonal imbalances; the clinical presentation dominated by manifestations of hyperandrogenism, which generates short- and long-term consequences on female health sterility, infertility is one of the most alarming associated morbidities. Forty women (28.9 ± 0.8 years old) with polycystic ovarian syndrome had infertility and there were enrolled in these clinical trials and randomly allocated into two groups. Group one and Group two were given treated infertility drugs (Clomid 5 mg for 5 days) and recombinant follicle-stimulating hormone (rFSH) 75 IU for long and short duration to get pregnant. Serum testosterone, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) of both groups were measured when women diagnosed as PCOS. The results showed that women which treated by low-dose recombinant FSH 75 IU for 3 days consequently (Group one) have significant decreased LH, while progesterone and FSH significantly increased after treated by hormone therapy P ≥ 0.05 while after treatment with recombinant FSH IU for 5 days (Group two), the result showed non-significant effect as compared with the first group. Concluded: Increase pregnant rate and decrease over stimulation syndrome among infertile women associated with polycystic overian syndrome, when treated with applicated low dose and short term by rFSH hormone.

Downloads

Download data is not yet available.

References

Badawy, A. and A. Elnashar. 2011. Treatment options for polycystic ovary syndrome. Int. J. Womens Health. 3: 25.

Blank, S. K., C. R. McCartney and J. C. Marshall. 2006. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum. Reprod. Update. 12(4): 351-361.

Blank, S. K., C. R. McCartney, S. Chhabra, K. D. Helm, C. A. Eagleson, R. J. Chang and J. C. Marshall. 2009. Modulation of gonadotropinreleasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls-implications for regulation of pubertal maturation. J. Clin. Endocrinol. Metab. 94(7): 2360-2366.

Brothers, K. J., S. Wu, S. A. DiVall, M. R. Messmer, C. R. Kahn, R. S. Miller, S. Radovick, F. E. Wondisford and A. Wolfe. 2010. Rescue of obesity-induced infertility in female mice due to a pituitary-specific knockout of the insulin receptor. Cell Metab. 12(3): 295-305.

Cameron, I. T., G. Irvine and J. E. Norman. 1996. Menstruation. In: Hiller, S. G., H. C. Kitchener and J. P. Neilson, editors. Scientific Essentials of REPRODUCTIVE MEDICINE. W.B. Saunders, London.

Chavez-Ross, A., S. Franks, H. D. Mason, K. Hardy and J. Stark. 1997. Modelling the control of ovulation and polycystic ovary syndrome. J. Math. Biol. 36(1): 95-118.

Christin-Maitre, S. and J. N. Hugues. 2003. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum. Reprod. 18(8): 1626-1631.

Cristello, F., V. Cela, P. G. Artini and A. R. Genazzani. 2005. Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol. Endocrinol. 21(6): 340-352.

Dunaif, A., K. R. Segal, W. Futterweit and A. Dobrjansky. 1989. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 38(9): 1165-1174.

Filicori, M. 1999. The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil. Steril. 71(3): 405-414.

Fritz, M. A., L. Speroff and M. J. del Sol Jaquotot. 2011. Endocrinología Ginecológica Clínica y Esterilidad. Wolters Kluwer Health, Lippincott Williams & Wilkins, Philadelphia, PA.

Goldenberg, N. and C. Glueck. 2008. Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva Ginecol. 60(1): 63-75.

Gorry, A., D. M. White and S. Franks. 2006. Infertility in polycystic ovary syndrome. Endocrine. 30(1): 27-33.

Hack, M., M. Brish, D. M. Serr, V. Insler, M. Salomy and B. Lunenfeld. 1972. Outcome of pregnancy after induced ovulation: Followup of pregnancies and children born after clomiphene therapy. JAMA. 220(10): 1329-1333.

Hopkinson, Z. E., N. Sattar, R. Fleming and I. A. Greer. 1998. Polycystic ovarian syndrome: The metabolic syndrome comes to gynaecology. BMJ. 317(7154): 329-332.

Johnson, N. P. 2014. Metformin use in women with polycystic ovary syndrome. Ann. Transl. Med. 2(6): 56.

Karkanaki, A., C. Vosnakis and D. Panidis. 2011. The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology. Hormones. 10(2): 95-103.

Lobo, R. A. and E. Carmina. 2000. The importance of diagnosing the polycystic ovary syndrome. Ann. Intern. Med. 132(12): 989-993.

Mascarenhas, M. N., S. R. Flaxman, T. Boerma, S. Vanderpoel and G. A. Stevens. 2012. National, regional, and global trends in infertility prevalence since 1990: A systematic analysis of 277 health surveys. PLoS Med. 9(12): e1001356.

Morgante, G., R. Orvieto, A. Di Sabatino, M. C. Musacchio and V. De Leo. 2011. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil. Steril. 95: 2642-2644.

Norman, R. J. 2002. Hyperandrogenaemia and the ovary. Mol. Cell. Endocrinol. 191(1): 113-119.

Pasquali, R. and F. Casimirri. 1993. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin. Endocrinol. 39(1): 1-16.

Pierre, A., M. Peigné, M. Grynberg, N. Arouche, J. Taieb, L. Hesters, J. Gonzalès, J. Y. Picard, D. Dewailly, R. Fanchin and S. Catteau-Jonard. 2013. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. Hum. Reprod. 28(3): 762-769.

Practice Committee of the American Society for Reproductive Medicine. 2012. Diagnostic evaluation of the infertile female: A committee opinion. Fertil. Steril. 98(2): 302-307.

Qiao, J. and H. L. Feng. 2011. Extra-and intra-ovarian factors in polycystic ovary syndrome: Impact on oocyte maturation and embryo developmental competence. Hum. Reprod. Update. 17(1): 17-33.

Rothchild, I. 1983. Role of progesterone in initiating and maintaining pregnancy. In: Progesterone and Progestins. Raven Press, New York. p219-229.

Shoham, Z., H. S. Jacobs and V. Insler. 1993. Luteinizing hormone: Its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase. Fertil. Steril. 59(6): 1153-1161.

Taymar, M. l. 1996. Regulation of follicle growth: some clinical implications in reproductive endocrinology. Fertil. Steril. 65: 235- 247.

Thessaloniki, T. 2008. PCOS consensus workshop group consensus on infertility treatment related to polycystic ovary syndrome. Fertil. Steril. 89: 505-522.

Willis, D. S., H. Watson, H. D. Mason, R. Galea, M. Brincat and S. Franks. 1998. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: Relevance to mechanism of anovulation. J. Clin. Endocrinol. Metab. 83(11): 3984-3991.

Published

2020-06-30

How to Cite

Umer, S. Q., & Sadeq, T. W. (2020). Management Infertility by Hormones Replacement Therapy in Women with Polycystic Ovarian Syndrome. Polytechnic Journal, 10(1), 170-174. https://doi.org/10.25156/ptj.v10n1y2020.pp170-174

Issue

Section

Research Articles